Direct-acting antiviral therapy reduces variceal rebleeding and improves liver function in hepatitis C virus-related cirrhosis: A multicenter retrospective cohort study

Table 16 Laboratory results at 5-year follow-up

Parameter	Group A (DAA-Treated)	Group B (Non-DAA-Treated)	P value
Hemoglobin (g/dL)	14.2 ± 1.3	12.5 ± 1.8	< 0.001
Platelet count (10³/μL)	180.5 ± 40.2	130.4 ± 35.6	< 0.001
Serum creatinine (mg/dL)	0.8 ± 0.2	1.2 ± 0.3	< 0.001
Albumin (g/dL)	4.0 ± 0.5	3.2 ± 0.6	< 0.001
INR	1.2 ± 0.3	1.6 ± 0.4	< 0.001
ALT (U/L)	25 ± 10	45 ± 15	< 0.001
AST (U/L)	30 ± 12	50 ± 18	< 0.001
Bilirubin (mg/dL)	1.0 ± 0.5	2.5 ± 1.0	< 0.001
Alkaline phosphatase (U/L)	90 ± 20	130 ± 30	< 0.001
Liver Stiffness (FibroScan) LSM (kPa)	10.5 ± 1.8	16.0 ± 2.5	< 0.001
MELD score	7 ± 2	12 ± 3	< 0.001
Child-Pugh class A (%)	95	60	< 0.001
Child-Pugh class B (%)	5	40	< 0.001

INR: International normalized ratio; LSM: Liver stiffness measures; MELD: Model for end-stage liver disease; DAA: Direct-acting antiviral; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.